A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA). A double-blind , randomised, phase 3b, parallel-group study to compare the effects of rosuvastatin with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment.

Trial Profile

A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA). A double-blind , randomised, phase 3b, parallel-group study to compare the effects of rosuvastatin with placebo on assessment of survival and cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2011

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms AURORA
  • Most Recent Events

    • 10 Nov 2009 Actual number of patients changed from 2775 to 2776 as reported by ClinicalTrials.gov.
    • 30 Mar 2009 Results presented as a late-breaking abstract at 58th Annual Scientific Session of the American College of Cardiology and published in the New England Journal of Medicine.
    • 18 Mar 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top